Regenxbio INC

REGENXBIO Inc. announced the pricing of a public offering of common stock and pre-funded warrants, expecting to raise approximately $100 million.

REGENXBIO announced the first patient dosed in a Phase IIb/III trial for diabetic retinopathy, triggering a $100 million milestone payment from AbbVie.

REGENXBIO Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors, ratification of auditors, and approval of a stock option exchange program for non-executive employees.

REGENXBIO announced positive topline results from its pivotal Phase III AFFINITY DUCHENNE study of RGX-202 for Duchenne muscular dystrophy, achieving its primary endpoint with high statistical significance.

REGENXBIO Inc. has reached a settlement with GlaxoSmithKline LLC, agreeing to pay $10.0 million to resolve a dispute over sublicense fees.

REGENXBIO reported its fourth quarter and full year 2025 financial results, highlighting advancements in its gene therapy pipeline alongside regulatory challenges for its MPS programs.

REGENXBIO Inc. files its Q1 2026 10-Q, detailing significant revenue decline, increased R&D expenses, and ongoing clinical trial progress.

REGENXBIO Inc. reported a reduced net loss for the nine months ended September 30, 2025, driven by increased collaboration revenue, while advancing multiple gene therapy programs including ABBV-RGX-314, RGX-202, and RGX-121.

REGENXBIO Inc. reported increased revenue driven by a new collaboration, secured a significant royalty bond, and advanced its gene therapy pipeline despite widening net losses.

REGENXBIO's Q1 2025 revenue surged due to a collaboration with Nippon Shinyaku, offsetting increased operating expenses and resulting in a net income of $6.1 million.

REGENXBIO's Q3 2024 report details financial results, clinical trial progress, and strategic updates, including a focus on key gene therapy programs.

REGENXBIO's Q2 2024 report highlights progress in clinical trials, financial updates, and a leadership transition.

REGENXBIO reported increased revenues and a reduced net loss in 2025, driven by new partnerships, but faces significant regulatory setbacks for its MPS I and MPS II gene therapies and a going concern warning.

REGENXBIO Inc.'s 2024 10-K filing details the company's financial performance, pipeline advancements, and strategic collaborations, including partnerships with AbbVie and Nippon Shinyaku.

REGENXBIO Inc. released its 10-K filing, detailing its financial results for 2023 and providing updates on its clinical-stage gene therapy programs.

REGENXBIO Inc. executive Curran Simpson reports transactions related to the Employee Stock Purchase Plan and tax withholdings for restricted stock units.

REGENXBIO Chief Medical Officer Steve Pakola executed a Rule 10b5-1 plan transaction involving the acquisition and disposition of company stock.

REGENXBIO Inc. Chief Medical Officer Steve Pakola reported transactions involving the sale of common stock and the exercise of stock options, executed under a pre-arranged trading plan.

Director Daniel Tasse was granted 9,807 restricted stock units and 46,600 stock options as part of annual equity compensation.

Director David C. Stump was granted 9,807 restricted stock units and 46,600 stock options by REGENXBIO Inc.

Director Jennifer Zachary was granted 9,807 restricted stock units and 46,600 stock options by REGENXBIO Inc.

REGENXBIO Inc. announced its 2026 Annual Meeting of Stockholders, scheduled for May 29, 2026, to elect directors, ratify auditor selection, and vote on executive compensation and stock option exchange proposals.

REGENXBIO Inc. has filed a definitive proxy statement with the SEC.

REGENXBIO Inc. has released its proxy statement for the upcoming Annual Meeting of Stockholders to be held on May 30, 2025, outlining key proposals including the election of directors, ratification of the accounting firm, and approval of the 2025 Equity Incentive Plan.

REGENXBIO Inc. has filed a definitive proxy statement with the SEC.

REGENXBIO Inc.'s proxy statement outlines proposals for the upcoming annual meeting, including director elections, ratification of the accounting firm, and an advisory vote on executive compensation.

JPMorgan Chase & Co. has filed a Schedule 13G, reporting beneficial ownership of 4.4% of REGENXBIO Inc.'s common stock as of May 29, 2026.

State Street Corporation has reported beneficial ownership of 5.3% of REGENXBIO Inc.'s common stock as of March 31, 2026.

The Vanguard Group reports 0% beneficial ownership in REGENXBIO Inc. following an internal realignment that disaggregated reporting responsibilities to its subsidiaries.

BlackRock Portfolio Management LLC has filed an amended Schedule 13G, reporting a 4.1% passive ownership stake in REGENXBIO INC as of December 31, 2025.

Redmile Group, LLC and its affiliates have reported a 9.9% beneficial ownership stake in REGENXBIO Inc., totaling 5,062,477 shares.

BlackRock Portfolio Management LLC has disclosed a 6.2% beneficial ownership stake in REGENXBIO INC, totaling 3,133,608 common shares, as of June 30, 2025.